J
Jan Vilcek
Researcher at New York University
Publications - 353
Citations - 26496
Jan Vilcek is an academic researcher from New York University. The author has contributed to research in topics: Interferon & Tumor necrosis factor alpha. The author has an hindex of 82, co-authored 353 publications receiving 26148 citations. Previous affiliations of Jan Vilcek include York University & Czechoslovak Academy of Sciences.
Papers
More filters
Journal ArticleDOI
Immune response in mice that lack the interferon-gamma receptor.
Sui Huang,Wiljan Hendriks,Alana Althage,Silvio Hemmi,Horst Bluethmann,Ryutaro Kamijo,Jan Vilcek,Rolf M. Zinkernagel,Michel Aguet +8 more
TL;DR: Mutant mice offer the possibility for the further elucidation of IFN-gamma-mediated functions by transgenic cell- or tissue-specific reconstitution of a functional receptor.
Journal Article
Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities.
Junming Le,Jan Vilcek +1 more
Journal ArticleDOI
Requirement for transcription factor IRF-1 in NO synthase induction in macrophages.
Ryutaro Kamijo,Hisashi Harada,Toshifumi Matsuyama,Maarten C. Bosland,J. Gerecitano,Deborah Shapiro,Junming Le,S. I. Koh,Tohru Kimura,Shawn J. Green,T. W. Mak,Tadatsugu Taniguchi,Jan Vilcek +12 more
TL;DR: Macrophages from mice with a targeted disruption of the IFN regulatory factor-1 (IRF-1) gene produced little or no NO and synthesized barely detectable iNOS messenger RNA in response to stimulation, and infection with Mycobacterium bovis was more severe in IRf-1-/- mice than in wild-type mice.
Journal Article
New insights into the molecular mechanisms of its multiple actions
Jan Vilcek,T. H. Lee +1 more
Journal ArticleDOI
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
David M. Knight,H Trinh,J Le,Scott A. Siegel,David J. Shealy,M McDonough,Bernard Scallon,M A Moore,Jan Vilcek,P Daddona +9 more
TL;DR: The chimeric A2 antibody (cA2) exhibits better binding and neutralizing characteristics than the murine A2 which was shown to contain a mixture of two kappa light chains, and suggest that it will have advantages over existing murine anti-TNF antibodies for clinical use.